Fadia Qiryaqos
0009-0001-9244-9256
Mirati Therapeutics (United States)
1 paper found
Refreshing results…
The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading
Missing publications? Search for publications with a matching author name.